OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!
If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.
Requested Article:
Therapeutic drug monitoring in Crohn’s disease patients treated with anti-TNF: a comparison of two techniques
Giorgia Bodini, Maria Giulia Demarzo, Afscin Djahandideh Sheijani, et al.
European Journal of Gastroenterology & Hepatology (2021) Vol. 34, Iss. 4, pp. 382-388
Closed Access | Times Cited: 6
Giorgia Bodini, Maria Giulia Demarzo, Afscin Djahandideh Sheijani, et al.
European Journal of Gastroenterology & Hepatology (2021) Vol. 34, Iss. 4, pp. 382-388
Closed Access | Times Cited: 6
Showing 6 citing articles:
Serum oncostatin M predicts mucosal healing in patients with inflammatory bowel diseases treated with anti-TNF, but not vedolizumab
Lorenzo Bertani, Brigida Barberio, Marco Fornili, et al.
Digestive and Liver Disease (2022) Vol. 54, Iss. 10, pp. 1367-1373
Closed Access | Times Cited: 15
Lorenzo Bertani, Brigida Barberio, Marco Fornili, et al.
Digestive and Liver Disease (2022) Vol. 54, Iss. 10, pp. 1367-1373
Closed Access | Times Cited: 15
Optimizing therapeutic drug monitoring in inflammatory bowel disease: a focus on therapeutic monoclonal antibodies
Konstantinos Papamichael, Adam S. Cheifetz
Expert Opinion on Drug Metabolism & Toxicology (2021) Vol. 17, Iss. 12, pp. 1423-1431
Closed Access | Times Cited: 7
Konstantinos Papamichael, Adam S. Cheifetz
Expert Opinion on Drug Metabolism & Toxicology (2021) Vol. 17, Iss. 12, pp. 1423-1431
Closed Access | Times Cited: 7
Treatment and Management of Chronic Inflammatory Bowel Diseases: Optimizing Present and Future Therapeutic Choices
Lorenzo Bertani
Journal of Clinical Medicine (2022) Vol. 11, Iss. 18, pp. 5267-5267
Open Access | Times Cited: 5
Lorenzo Bertani
Journal of Clinical Medicine (2022) Vol. 11, Iss. 18, pp. 5267-5267
Open Access | Times Cited: 5
Comparing Point-of-Care Technology to ELISA Testing for Infliximab and Adalimumab Levels in Adult Inflammatory Bowel Disease Patients: A Prospective Pilot Study
Erica Bonazzi, Daria Maniero, Greta Lorenzon, et al.
Diagnostics (2024) Vol. 14, Iss. 19, pp. 2140-2140
Open Access
Erica Bonazzi, Daria Maniero, Greta Lorenzon, et al.
Diagnostics (2024) Vol. 14, Iss. 19, pp. 2140-2140
Open Access
Letter: predictive factors for treatment discontinuation in IBD—anti‐TNF trough levels and anti‐drug antibodies
Maria Giulia Demarzo, Giorgia Bodini, Elisabetta Giuliana, et al.
Alimentary Pharmacology & Therapeutics (2021) Vol. 54, Iss. 4, pp. 536-537
Open Access | Times Cited: 1
Maria Giulia Demarzo, Giorgia Bodini, Elisabetta Giuliana, et al.
Alimentary Pharmacology & Therapeutics (2021) Vol. 54, Iss. 4, pp. 536-537
Open Access | Times Cited: 1
Therapeutic Drug Monitoring in Practice for Inflammatory Bowel Disease
Bryant Megna, Byron P. Vaughn
Current Gastroenterology Reports (2022) Vol. 24, Iss. 12, pp. 191-200
Closed Access
Bryant Megna, Byron P. Vaughn
Current Gastroenterology Reports (2022) Vol. 24, Iss. 12, pp. 191-200
Closed Access
